Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Income: 2022-2024

Historic Operating Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to -$217.3 million.

  • Day One Biopharmaceuticals' Operating Income fell 181.83% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.6 million, marking a year-over-year increase of 21.67%. This contributed to the annual value of -$217.3 million for FY2024, which is 5.44% down from last year.
  • Day One Biopharmaceuticals' Operating Income amounted to -$217.3 million in FY2024, which was down 5.44% from -$206.1 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Operating Income peaked at -$146.9 million during FY2022, and registered a low of -$217.3 million during FY2024.
  • For the 3-year period, Day One Biopharmaceuticals' Operating Income averaged around -$190.1 million, with its median value being -$206.1 million (2023).
  • Data for Day One Biopharmaceuticals' Operating Income shows a maximum YoY slumped of 40.27% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Operating Income stood at -$146.9 million in 2022, then crashed by 40.27% to -$206.1 million in 2023, then fell by 5.44% to -$217.3 million in 2024.